-aminohippurate, also known as -aminohippuric acid (PAH), is used clinically to measure effective renal plasma flow. Preclinically, it was shown to reduce Lu-DOTATOC uptake in the kidneys while improving bioavailability compared with amino acid (AA) coinfusion. We report the safety and efficacy of PAH coinfusion during peptide receptor radiotherapy in patients with neuroendocrine tumors.
View Article and Find Full Text PDFPurpose: The aim of this study was to investigate conditions for reliable quantification of sub-centimeter lesions with lowF,Ga, andI uptake using a silicon photomultiplier-based PET/CT system.
Methods: A small tumor phantom was investigated under challenging but clinically realistic conditions resembling prostate and thyroid cancer lymph node metastases (6 spheres with 3.7-9.
PET imaging using the somatostatin receptor 2 (SSTR2) antagonist satoreotide trizoxetan (SSO-120, previously OPS-202) could offer accurate tumor detection and screening for SSTR2-antagonist radionuclide therapy in patients with SSTR2-expressing small cell lung cancer (SCLC). The aim of this single-center study was to investigate tumor uptake and detection rates of Ga-SSO-120 in comparison to F-FDG PET in the initial staging of SCLC patients. Patients with newly diagnosed SCLC who underwent additional whole-body Ga-SSO-120 PET/CT during the initial diagnostic workup were retrospectively included.
View Article and Find Full Text PDFWe present an overview of our prospective fibroblast-activation protein inhibitor (FAPI) registry study across a 3-y period, with head-to-head comparison of tumor uptake in Ga-FAPI and F-FDG PET, as well as FAP immunohistochemistry. This is an interim analysis of the ongoing Ga-FAPI PET prospective observational trial at our department. Patients who underwent clinical imaging with Ga-FAPI PET between October 2018 and October 2021 were included.
View Article and Find Full Text PDFBackground: New-generation silicon-photomultiplier (SiPM)-based PET/CT systems exhibit an improved lesion detectability and image quality due to a higher detector sensitivity. Consequently, the acquisition time can be reduced while maintaining diagnostic quality. The aim of this study was to determine the lowest F-FDG PET acquisition time without loss of diagnostic information and to optimise image reconstruction parameters (image reconstruction algorithm, number of iterations, voxel size, Gaussian filter) by phantom imaging.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
November 2022
Purpose: Both digital positron emission tomography (PET) detector technologies and artificial intelligence based image post-reconstruction methods allow to reduce the PET acquisition time while maintaining diagnostic quality. The aim of this study was to acquire ultra-low-count fluorodeoxyglucose (FDG) ExtremePET images on a digital PET/computed tomography (CT) scanner at an acquisition time comparable to a CT scan and to generate synthetic full-dose PET images using an artificial neural network.
Methods: This is a prospective, single-arm, single-center phase I/II imaging study.
Purpose: The determination of the glomerular filtration rate (GFR) is decisive for a variety of clinical issues, for example, to monitor the renal function in radionuclide therapy patients. Renal scintigraphy using glomerularly filtered tracers allows combined acquisition of renograms and GFR estimation but requires repeated blood sampling for several hours. In contrast, dynamic PET imaging using the glomerularly filtered tracer [Ga]Ga-DOTA bears the potential to non-invasively estimate the GFR by compartmental kinetic modelling.
View Article and Find Full Text PDFRadioembolization is the selective application of radionuclide-loaded microspheres into liver arteries for the therapy of liver tumours and metastases. In this review, we focused on therapy planning and dosimetry, as well as the main indications of 90Y-glass and resin microspheres and 166Ho-microspheres.
View Article and Find Full Text PDFBackground: A variety of therapeutic approaches are employed to treat patients suffering from breast cancer. Likewise, a broad spectrum of imaging ligands has been introduced for noninvasive positron emission tomography/computed tomography (PET/CT) imaging to enable comprehensive tumor characterization and more accurate response evaluation.
Summary: In recent years, novel radioactively labeled ligands have been developed for PET/CT imaging in metastatic breast cancer.
Fibroblast activation protein inhibitor (FAPI) PET/CT is a new tool in the diagnostic workup of cancer. With a growing volume of applications, pitfalls and common findings need to be considered for Ga-FAPI PET/CT image interpretation. The aim of this study was to summarize common findings and report pitfalls in Ga-FAPI PET/CT.
View Article and Find Full Text PDFBackground: In recurrent differentiated thyroid cancer patients, detectability in I PET is limited for lesions with low radioiodine uptake. We assess the improvements in lesion detectability and image quality between three generations of PET scanners with different detector technologies. The results are used to suggest an optimized protocol.
View Article and Find Full Text PDFHepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. A growing number of local and systemic therapies are available, and accurate staging is critical for management decisions. We assessed the impact of neovasculature imaging by Ga-PSMA-11 PET/CT on disease staging, prognostic groups, and management of patients with HCC compared with staging with CT.
View Article and Find Full Text PDFBackground: The superior accuracy and sensitivity of F-FDG-PET/CT in comparison to morphological imaging alone leads to an upstaging in up to 30% of lymphoma patients. Novel digital PET/CT scanners might enable to reduce administered tracer activity or scan time duration while maintaining diagnostic performance; this might allow for a higher patient throughput or a reduced radiation exposure, respectively. In particular, the radiation exposure reduction is of interest due to the often young age and high remission rate of lymphoma patients.
View Article and Find Full Text PDF[Ra]RaCl2 dichloride treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) is associated with improved overall survival (OS) and a delay in the time to the first symptomatic skeletal-related event. The aim of this study was to evaluate the quality of life (QoL) of patients with mCRPC receiving [Ra]RaCl2 treatment using the European Organization for Research and Treatment of Cancer (EORTC) validated questionnaire form.Thirty patients with mCRPC were included in this study.
View Article and Find Full Text PDF